282 related articles for article (PubMed ID: 29189317)
21. [Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice].
Michel M; Reguiai Z; Fauconier M; Brochot P; Eschard JP; Salmon JH
Therapie; 2016 Jun; 71(3):281-6. PubMed ID: 27235651
[TBL] [Abstract][Full Text] [Related]
22. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
23. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy.
Lis-Święty A; Skrzypek-Salamon A; Arasiewicz H; Brzezińska-Wcisło L
Allergol Int; 2015 Oct; 64(4):382-3. PubMed ID: 26433537
[No Abstract] [Full Text] [Related]
24. A review of ustekinumab in the treatment of psoriatic arthritis.
Roberts J; O'Rielly DD; Rahman P
Immunotherapy; 2018 Apr; 10(5):361-372. PubMed ID: 29439608
[TBL] [Abstract][Full Text] [Related]
25. Ustekinumab associated with flares of psoriatic arthritis.
Stamell EF; Kutner A; Viola K; Cohen SR
JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
[TBL] [Abstract][Full Text] [Related]
26. Ustekinumab Improves Paradoxical Enteropathy Associated With Psoriasis Arthritis.
Urushikubo J; Kawasaki K; Eizuka M; Yanai S; Nakamura S; Sugai T; Matsumoto T
Inflamm Bowel Dis; 2019 Sep; 25(10):e128-e129. PubMed ID: 31300828
[No Abstract] [Full Text] [Related]
27. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
[No Abstract] [Full Text] [Related]
28. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
[No Abstract] [Full Text] [Related]
29. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
Fujita Y; Shinkuma S; Nomura T; Shimizu H
Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
[No Abstract] [Full Text] [Related]
30. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
Shaw CA; Kole LCS; Elewski BE
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e431-e432. PubMed ID: 31220373
[No Abstract] [Full Text] [Related]
31. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
33. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment.
Hambly R; Kelly A; Gilhooley E; Nic Dhonncha E; Murad A; Hughes R; Lally A; Kirby B
Br J Dermatol; 2018 Jan; 178(1):e46-e48. PubMed ID: 28762482
[No Abstract] [Full Text] [Related]
34. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald JM; Klufas DM; Strober BE
J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
[TBL] [Abstract][Full Text] [Related]
35. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.
Nakayama C; Fujita Y; Watanabe M; Shimizu H
J Dermatol; 2015 Oct; 42(10):996-8. PubMed ID: 26010891
[TBL] [Abstract][Full Text] [Related]
36. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation.
Dressler C; Eisert L; Pham PA; Nast A
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1249-1260. PubMed ID: 30735612
[TBL] [Abstract][Full Text] [Related]
38. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
Lund T; Thomsen SF
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
[TBL] [Abstract][Full Text] [Related]
40. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
